Note 18: Other–Net, (Income) Expense:
Other–net, (income) expense consisted of the following:
|
| | | | | | | | | | | |
| 2013 | | 2012 | | 2011 |
Income related to termination of the exenatide collaboration with Amylin (Note 4) | $ | (495.4 | ) | | $ | (787.8 | ) | | $ | — |
|
Interest expense | 160.1 |
| | 177.8 |
| | 186.0 |
|
Interest income | (119.7 | ) | | (105.0 | ) | | (79.9 | ) |
Other (income) expense | (63.9 | ) | | 41.0 |
| | 72.9 |
|
Other–net, (income) expense | $ | (518.9 | ) | | $ | (674.0 | ) | | $ | 179.0 |
|
For the years ended December 31, 2013 and 2012, other–net, (income) expense primarily consists of income associated with the termination of the exenatide collaboration with Amylin, including income recognized from the transfer to Amylin of exenatide commercial rights in all markets outside the U.S. in 2013 and income recognized from the early payment of the exenatide revenue-sharing obligation by Amylin in 2012. See Note 4 for additional information. For the year ended December 31, 2011, other–net, (income) expense primarily consists of the impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 8) partially offset by gains on the disposal of investment securities.
